Author: Wioletta Rut; Katarzyna Groborz; Linlin Zhang; Xinyuanyuan Sun; Mikolaj Zmudzinski; Rolf Hilgenfeld; Marcin Drag
Title: Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design Document date: 2020_3_8
ID: e8qubwha_2
Snippet: Hubei province, China. [1] Symptoms of the first patients were flu-like and included fever, cough and myalgia, but with a tendency to develop a potentially fatal dyspnea and acute respiratory distress syndrome. [1b] Genetic analysis confirmed a betacoronavirus as the causing agent. The virus was initially named 2019 novel coronavirus (2019-nCoV), [1] [2] but shortly thereafter, it was renamed to SARS-CoV-2. [3] By March 07, 2020, the WHO had regi.....
Document: Hubei province, China. [1] Symptoms of the first patients were flu-like and included fever, cough and myalgia, but with a tendency to develop a potentially fatal dyspnea and acute respiratory distress syndrome. [1b] Genetic analysis confirmed a betacoronavirus as the causing agent. The virus was initially named 2019 novel coronavirus (2019-nCoV), [1] [2] but shortly thereafter, it was renamed to SARS-CoV-2. [3] By March 07, 2020, the WHO had registered >100,000 cumulative cases, in 65 countries, of coronavirus disease 2019 (COVID-19), with >3400 deaths. [4] Currently, there is no approved vaccine or treatment for COVID-19. Efforts are being made to characterize molecular targets, pivotal for the development of anti-coronaviral therapies. [5] The main protease (M pro , also known as 3CL pro ), is one of coronaviral nonstructural proteins (Nsp5) designated as a potential target for drug development. [6] M pro cleaves the viral polyproteins, generating twelve non-structural proteins (Nsp4-Nsp16),
Search related documents:
Co phrase search for related documents- cause agent and distress syndrome: 1
- cause agent and genetic analysis: 1
- China Hubei province and cumulative case: 1, 2
- China Hubei province and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- China Hubei province and drug development: 1, 2, 3, 4, 5, 6, 7, 8
- China Hubei province and genetic analysis: 1, 2
- China Hubei province and Hubei province: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- China Hubei province and main protease: 1, 2, 3, 4
- cumulative case and Hubei province: 1, 2, 3, 4, 5, 6, 7
- distress syndrome and drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- distress syndrome and drug development potential target: 1
- distress syndrome and genetic analysis: 1, 2, 3, 4
- distress syndrome and Hubei province: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- distress syndrome and main protease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- distress syndrome and molecular target: 1, 2, 3, 4
- drug development and genetic analysis: 1, 2, 3, 4
- drug development and Hubei province: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- drug development and main protease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- drug development and molecular target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Co phrase search for related documents, hyperlinks ordered by date